HST Global, Inc. Stock Other OTC
Equities
HSTC
US40432E2028
Biotechnology & Medical Research
Financials (USD)
Sales 2022 | - | Sales 2023 | - | Capitalization | 3.19M |
---|---|---|---|---|---|
Net income 2022 | - | Net income 2023 | - | EV / Sales 2022 | - |
Net Debt 2022 | 75.89K | Net Debt 2023 | 96.79K | EV / Sales 2023 | - |
P/E ratio 2022 |
-4.34
x | P/E ratio 2023 |
-21.8
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 37.71% |
Managers | Title | Age | Since |
---|---|---|---|
Ron Howell
CEO | Chief Executive Officer | 75 | 08-05-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ron Howell
CEO | Chief Executive Officer | 75 | 08-05-07 |
1st Jan change | Capi. | |
---|---|---|
+1.88% | 42.59B | |
+8.44% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.96% | 24.81B | |
-24.41% | 18.17B | |
+28.89% | 12.05B | |
-2.80% | 11.7B | |
+7.26% | 11.1B |